Zusammenfassung
Coenzym Q10 ist eine natürlich vorkommende, lipophile Verbindung bestehend aus einer
ringförmigen Chinonstruktur, die in allen lebenden Zellen vorkommt. Es fungiert als
ein wichtiger Cofaktor bei der Energiegewinnung innerhalb der Mitochondrien. Mit zunehmendem
Alter und unter Einfluss einiger Medikamente nimmt die Coenzym-Q10-Konzentration im
Körper ab, wobei diese Abnahme in den verschiedenen Organen unterschiedlich ausgeprägt
ist. Die Abnahme der Coenzym-Q10-Konzentration der verschiedenen Organe könnte mit
ein Grund für deren altersbedingten Funktionsverlust darstellen, dem durch eine Supplementation
begegnet werden könnte. Ferner haben diverse Studien wiederholt gezeigt, dass eine
Vielzahl von Krankheitsbildern - allen voran Herz-Kreislauf-Erkrankungen - gut auf
eine Behandlung mit Coenzym Q10 ansprechen, und das ohne nennenswerte Nebenwirkungen.
In wieweit sich Coenzym Q10 in der Therapie etablieren wird, bleibt abzuwarten.
Summary
Coenzyme Q10 is a lipophilic compound with an annular quinone structure widely distributed
in all living cells. It functions as an important cofactor involved in the energy
generation of mitochondria. As a person grows older and influenced by certain medicaments
the coenzyme Q10 concentration in the body will decrease, varying with individual
organs. This variation of the Q10 concentration in individual organs is considered
to be the reason for their property to lose their efficacy with growing age, a fact
that could be counteracted by supplementation. Moreover, several studies have come
to the conclusion that a great number of diseases - primarily heart and circulatory
disorders - will positively respond to a treatment with coenzyme Q10, even without
significant side effects. It remains to be seen whether coenzyme Q10 will become a
standard therapy.
Schlüsselwörter
Coenzym Q10 - Funktion - Supplementation - Herz-Kreislauf-Erkrankungen - Alter
Key words
Coenzyme Q10 - ubiquinones - function - supplementation - heart and circulatory diseases
- age
Literatur
- 1
Folkers K, Langsjoen P, Willis R, Richardson P. et al. .
Lovastatin decreases coenzyme Q levels in humans.
Proc Natl Acad Sci USA.
1990;
87
8931-8934
- 2
Folkers K, Osterborg A, Nylander M. et al. .
Activities of vitamin Q10 in animal models and a serious deficiency in patients with
cancer.
Biochem Biophys Res Comm.
1997;
234
296-299
- 3
Godsland IF, Stevenson JC.
Insulin resistance: syndrome or tendency?.
Lancet.
1995;
346
100-103
- 4
Grundy SM.
Hypertriglyceridemia, insulin resistance, and the metabolic syndrome.
Am J Cardiol.
1999;
83
25-29
- 5
Hamada M, Kazatani Y, Ochi T, Ito T, Kokubu T.
Correlation between serum CoQ10 level and myocardial contractility in hypertensive
patients. Biomedical and Clinical Aspects of Coenzyme Q.
Amsterdam: Elsevier.
1984;
4
263-270
- 6
Jolliet P, Simon N, Barre J. et al. .
Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences.
Int J Clin Pharmacol Ther.
1998;
36
506-509
- 7
Judy WV, Folkers K, Hall JH.
Improved long-term survival in coenzyme Q10 treated congestive heart failure patients
compared to conventionally treated patients.
In: Folkers K, Littarru GP, Yamagami T (eds.): Biomedical and Clinical Aspects of
Coenzyme Q.
Amsterdam: Elsevier.
1991;
6
291-298
- 8
Judy WV. et al. .
Regression of prostate cancer and plasma specific antigens (PSA) in patients on treatment
with CoQ10.
First Conference of the International Coenzyme Q10 Association..
1998;
- 9
Kalen A, Appelkvist EL, Dallner G.
Age-related changes in the lipid compositions of rat and human tissues.
Lipids.
1989;
24
579-584
- 10
Kostner GM, Gavish D, Leopold B. et al. .
HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.
Circulation.
1989;
80
1313-1319
- 11
Kotchen TA.
Attenuation of hypertension by insulin-sensitizing agents.
Hypertension.
1996;
28
219-223
- 12
Kucharska J.
Deficit of coenzyme Q in heart and liver mitochondria of rats with streptozotocin-induced
diabetes.
Physiol Res.
2000;
49
411-418
- 13
Lockwood K, Moesgaard S, Folkers K.
Partial and complete regression of breast cancer in patients in relation to dosage
of coenzyme Q10.
Biochem Biophys Res Comm.
1994;
199
1504-1508
- 14
Lockwood K, Moesgaard S, Yamamoto T, Folkers K.
Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases.
Biochem Biophys Res Comm.
1995;
212
172-177
- 15
Ma A, Zhang W, Liu Z.
Effect of protection and repair of injury of mitochondrial membrane-phospholipid on
prognosis in patients with dilated cardiomyopathy.
Blood Press Suppl.
1996;
3
53-55
- 16
Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K.
Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial
failure.
Drugs Exp Clin Res.
1985;
11
581-593
- 17
Mortensen SA, Bouchelouche P, Muratsu K, Folkers K.
Clinical decline and relapse of cardiac patients on coenzyme Q10 withdrawal.
In: Folkers K, Yamamura Y (eds.): Biomedical and Clinical Aspects of Coenzyme Q.
Amsterdam: Elsevier.
1986;
5
281-290
- 18
Mortensen SA, Vadhanavikit S, Muratsu K, Folkers K.
Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific
breakthrough in the management of chronic heart failure.
Int J Tissue React.
1990;
12
155-162
- 19
Neuenschwander R, Burke BE, Olson RD.
Randomized, double-blind, placebo-controlled trial of coenzyme.
South Med J.
2001;
94
1112-1117
- 20
Preuss HG.
Effects of glucose/insulin perturbations on aging and chronic disorders of aging:
the evidence.
J Am Coll Nutr.
1997;
16
397-403
- 21
Richardson P, Drzewoski J, Ellis J, Shizukuishi S. et al. .
Reduction of elevated blood pressure by coenzyme Q10. Biomedical and Clinical Aspects
of Coenzyme Q.
Amsterdam: Elsevier.
1981;
3
229-234
- 22
Singh RB, Wander GS, Rastogi A. et al. .
Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with
acute myocardial infarction.
Cardiovasc Drugs Ther.
1998;
12
347-353
- 23
Singh RB, Niaz MA, Rastogi SS. et al. .
Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive
patients with coronary artery disease.
J Hum Hypertens.
1999;
13
203-208
- 24
Stetinova V.
Effects of known and potential antioxidants on animal models of pathological processes
(diabetes, gastric lesions, allergic bronchospasm).
Exp Toxicol Pathol.
2000;
52
473-479
- 25
Tsuyuasaki T, Noro C, Kikawada R.
Mechanocardiography of ischemic or hypertensive heart disease.
In: Yamamura Y, Folkers K (eds.): Biomedical and Clinical Aspects of Coenzyme Q.
Amsterdam: Elsevier.
1980;
2
273-288
- 26
Yamagami T, Takagi M, Akagami H, Kubo H. et al. .
Effect of coenzyme Q10 on essential hypertension, a double blind controlled study.
Biomedical and Clinical Aspects of Coenzyme Q.
Amsterdam: Elsevier.
1986;
5
337-343
Dr. (TR) Martin Deilmann
Hannoversche Straße 24
31848 Bad Münder
